Submissions from 2024
Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study, Guenther Koehne
A Machine Learning Approach To Predict Mortality Due To Immune-Mediated Thrombotic Thrombocytopenic Purpura, Camila Masias
A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura, Camila Masias Castanon
Irreversible Electroporation in Treating Colorectal Liver Metastases in Proximity to Critical Structures, Govindarajan Narayanan, Nicole Gentile, Jonathan Eyshi, Brian Schiro, Ripal Gandhi, Constantino Pena, Antonio Ucar, Santiago Aparo, Fernando de Zarraga, Sarah Joseph, Horacio Asbun, and Madelon Dijkstra
Submissions from 2023
Prognostic value of neutrophil/lymphocyte count in pancreas patients receiving ablative MR-guided RT, Michael Chuong, Robert Herrera, Muni Rubens, Antonio Ucar, Fernando De Zarraga, Santiago Aparo, Sarah Joseph, Matthew Hall, Rupesh Kotecha, Adeel Kaiser, and Gigi Estevez
Phase II trial of single-fraction SABR on 0.35T MRI-linac for thoracic, abdominal, and pelvic tumors, Michael Chuong, Kathryn Mittauer, Martin Tom, Noah Kalman, James McCulloch, Diane Alvarez, Paul Kaywin, Antonio Ucar, Federico Albrecht, Fernando De Zarraga, Santiago Aparo, Guilherme Rabinowits, Muni Rubens, Alonso Gutierrez, Rupesh Kotecha, and Carolina Rojas
Prospective Study Phase II Trial of Stereotactic MRI-Guided Adaptive Radiotherapy in 1 Fraction: Unplanned Interim Analysis, Michael Chuong, Kathryn Mittauer, Martin Tom, Noah Kalman, James McCulloch, Diane Alvarez, Paul Kaywin, Antonio Ucar, Federico Albrecht, Fernando De Zarraga, Santiago Aparo, Muni Rubens, Alonso Gutierrez, and Rupesh Kotecha
Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART), Roberto Herrera, Muni Rubens, Adeel Kaiser, Antonio Ucar, Fernando De Zarraga, Santiago Aparo, Horacio Asbun, Ramon Jimenez, and Michael Chuong
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results, Guenther Koehne
Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant, Guenther Koehne
Early integration of palliative care in malignant hematology, Marco Ruiz Andia and Jannelle Vicens
Submissions from 2022
Causes of death among inoperable pancreas cancer patients receiving 5-fraction ablative magnetic resonance image-guided radiation therapy prescribed to median biologically effective dose of 100 Gy, Michael Chuong, Robert Herrera, Matthew Hall, Rupesh Kotecha, Antonio Ucar, Fernando De Zarraga, Santiago Aparo, Govindarajan Narayanan, Horacio Asbun, Ramon Jimenez, Kathryn Mittauer, Alonso Gutierrez, Diane Alvarez, Tino Romaguera, James McCulloch, and Adeel Kaiser
Induction Chemotherapy and Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy for Inoperable Pancreas Cancer, Michael Chuong; Roberto Herrera; Adeel Kaiser; Muni Rubens; Tino Romaguera; Diane Alvarez; Rupesh Kotecha; Matthew Hall; James McCulloch; Antonio Ucar; Santiago Aparo; Sarah Joseph; Horacio Asbun; Ramon Jimenez; Govindarajan Narayanan; Alonso Gutierrez; and Kathryn , Mittauer
Induction chemotherapy and ablative 5-fraction stereotactic magnetic resonance guided adaptive radiation therapy for patients with initially inoperable adenocarcinoma of the pancreas, Michael Chuong, Robert Herrera, Muni Rubens, Adeel Kaiser, Rupesh Kotecha, Matthew Hall, James McCulloch, Antonio Ucar, Fernando De Zarraga, Santiago Aparo, Horacio Asbun, Domenech Asbun, Ramon Jimenez, Govindarajan Narayanan, Tino Romaguera, Diane Alvarez, Alonso Gutierrez, and Kathryn Mittauer
Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease, Camila Masias Castanon
Race, Rituximab, and Relapse in TTP, Camila Masias Castanon
Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension, Srikanth Nagalla
Evaluation of Anti-Factor Xa Level Usage for Low Molecular Weight Heparin in a Healthcare System, Natalie Quesep, Lourdes R. Menendez, Erika Dittmar, Radhan B. Gopalani, Payal Patel, and Srikanth Nagalla
Impact of Frailty on Hospital Outcomes Among Patients with Lymphoid Malignancies Receiving Autologous Hematopoietic Stem Cell Transplantation in the United States, Muni Rubens, Adrian Cristian, Venkataraghavan Ramamoorthy, Marco Ruiz Andia, Anshul Saxena, Peter McGranaghan, Raees Tonse, and Emir Veledar
Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer, Miguel Villalona Calero
Submissions from 2021
Mitigating the risk of transfusion-transmitted bacterial infections in hematology oncology patients, Harold Alvarez and Guenther Koehne
OC-0415 Long-term outcomes of MR-guided SABR & on-table adaptive replanning for unresectable pancreas cancer, Michael Chuong, Kathryn Mittauer, Tino Romaguera, Diane Alvarez, Rupesh Kotecha, Matthew Hall, Adeel Kaiser, John Bryant, James McCulloch, Antonio Ucar, Horacio Asbun, Govindarajan Narayanan, Alonso Gutierrez, Muni Rubens, and Robert Herrera
Ocular outcomes after treatment of cytomegalovirus (CMV) retinitis using adoptive immunotherapy with CMV-specific cytotoxic T-lymphocytes, Guenther Koehne
Ocular Outcomes after Treatment of Cytomegalovirus Retinitis Using Adoptive Immunotherapy with Cytomegalovirus-Specific Cytotoxic T Lymphocytes, Guenther Koehne
Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease, Srikanth Nagalla
Perspectives on the quality and utility of letters conforming to the AAIM guidelines, Srikanth Nagalla
Perceptions and Misperceptions of Early Palliative Care Interventions for Patients With Hematologic Malignancies Undergoing Bone Marrow Transplantation, Marco Ruiz Andia
Understanding Geriatrics-based Assessment in Hematologic Malignancies and Bone Marrow Transplant Patients, Marco Ruiz Andia and Adrian Cristian
Understanding Early Palliative Care Interventions for Patients With Hematologic Malignancies Undergoing Bone Marrow Transplantation, Corey Suthumphong and Marco Ruiz Andia
Submissions from 2020
Case report of ablative magnetic resonance-guided stereotactic body radiation therapy for oligometastatic mesenteric lymph nodes from bladder cancer, Michael Chuong, Diane Alvarez, Tino Romaguera, Kathryn Mittauer, Sonia Adamson, Alonso Gutierrez, Gustavo Luciani, Hayden Guerrero Olmo, and Antonio Ucar
Assessing Physical Function and Fatigue in Patients Selected to Undergo Bone Marrow Transplant, Adrian Cristian and Marco Ruiz Andia
Comparison of Function, Fatigue, Frailty in Patients with Malignant Hematology, Pre-Bone Marrow Transplant and Solid Tumors, Adrian Cristian and Marco Ruiz Andia
GRIP STRENGTH CHANGES IN BONE MARROW TRANSPLANT PATIENTS, Adrian Cristian and Marco Ruiz Andia
Abstract B054: Analysis of a cancer gene expression and next-generation sequencing dataset representing hispanic predominant South Florida population, Zuanel Diaz, Arpit Mehta, Zasha Pou, Muni Rubens, Don Parris, and Miguel Villalona Calero
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation, Guenther Koehne
Emerging Ablative and Transarterial Therapies for Pancreatic Cancer, Govindarajan Narayanan, Antonio Ucar, Ripal Gandhi, Arian Nasiri, Prasuna Inampudi, and Horacio Asbun
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study, Claudia Paba Prada
Bioengineered Exosomal Extracellular Vesicles in Cancer Therapeutics, Marco Ruiz Andia
Revisiting Early Palliative Care for Patients With Hematologic Malignancies and Bone Marrow Transplant: Why the Delay?, Marco Ruiz Andia
Evaluation of acute myeloid leukemia induction regimens in elderly patients with unfavorable risk cytogenetics that are candidates for intensive remission therapy, Monica Tadros, Guenther Koehne, Talia Zahra, Moe Shwin, Jessica Unzaga, and Nicholas Chow
Evaluating Acute Myeloid Leukemia Induction Regimens in Elderly Patients with Unfavorable Risk Cytogenetics That Are Candidates for Intensive Remission Therapy, Monica Tadros, Guenther Koehne, Talia Zahra, Jessica Unzaga, Moe Shwin, and Nicholas Chow
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers, Miguel Villalona Calero
Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology, Miguel Villalona Calero
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study, Miguel Villalona Calero
Submissions from 2019
Complications of Intrathecal Chemotherapy in Adults: Single-Institution Experience in 109 Consecutive Patients, Fernando Vargas Madueno
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer, Miguel Villalona Calero
Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic mice, Miguel Villalona Calero
Submissions from 2018
How I treat the young patient with multiple myeloma, Claudia Paba Prada
Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, Michael Troner
EML4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors, Fernando Vargas Madueno, Edwin Gould, Raul Valor, and Miguel Villalona Calero
Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer, Miguel Villalona Calero
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC), Miguel Villalona Calero
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden, Miguel Villalona Calero and Zuanel Diaz
Submissions from 2016
Global Overview of Colorectal Cancer ― Past, Present and Future, Antonio Ucar
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair, Miguel Villalona Calero